Gleevec

Type: Product
Name: Gleevec
First reported 8 hours ago - Updated 8 hours ago - 1 reports

US takes a dig at India’s IPR regime

MUMBAI: US has rapped India's weak intellectual property regime on the eve of Prime Minister Narendra Modi's visit to the country, saying US companies "seek to invest" in India, but "need transparent governance, a fair regulatory environment, and strong ... [Published Times of India - 8 hours ago]
First reported 9 hours ago - Updated 9 hours ago - 1 reports

La Grange cancer survivor lobbies for more research funding

Peter May, 75, felt like he had to make the trip to Washington, D.C. to talk with lawmakers about the urgent need for more cancer research funding and new legislation. The La Grange resident had a story to tell of survival, thanks to cutting-edge drug ... [Published Doings LaGrange - 9 hours ago]
First reported Sep 21 2014 - Updated Sep 21 2014 - 1 reports

Leukemia sufferers make drug plea

"With target-medication over the past decade, the disease has become much more treatable," said Kwong Yok-lam, chair professor at the University of Hong Kong's department of medicine.Glivec, a "smart" drug that targets cancer cells, has been available ... [Published Hong Kong Standard - Sep 21 2014]
First reported Sep 20 2014 - Updated Sep 20 2014 - 1 reports

New medications are making inroads in cancer battle

NEW YORK — About 1 in 22 Americans is a cancer survivor, triple the percentage seen 40 years ago, according to a report that suggests science may be slowly catching up with the deadly disease.About 14.5 million people in the United States have outlasted ... [Published Minneapolis Star Tribune - Sep 20 2014]
First reported Sep 20 2014 - Updated Sep 20 2014 - 1 reports

New Drug Saves Man with Non-Hodgkin's Lymphoma

Augusta, GA -Blood cancer has been known to claim the lives of its victims for several years, but with the help of a special drug a local man has prevailed.The last 14 years could have played out differently for Dean Beasley after doctors told him he ... [Published WJBF-TV - Sep 20 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

We need an ecosystem of innovation to retain our young scientists: Novartis India chief

Last September, Novartis India chief Ranjit Shahani stepped down as President of the Organisation of Pharmaceutical Producers of India, a global forumfor drugmakers.In April 2013, the Supreme Court delivered its judgment on a benchmark case involving ... [Published Hindu Business Line - Sep 19 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Synergy in drug research success

GLIVEC (or Gleevec in the US) is an anti-leukaemic drug known by several monikers - a miracle drug, a magic bullet, a blockbuster. It is a fine example of targeted therapy against certain leukaemia and solid cancers, but a lesser known fact is that it ... [Published Business Times Singapore - Sep 19 2014]
Entities: Gleevec, Drugs, Synergism
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

The Downfall of Pharmaceutical Innovation

REUTERS.COMIndia, the emerging pharmaceutical powerhouse of the developing world, has recently become a battleground between generic and private pharmaceutical companies as they pit public health interests against intellectual property rights. As demand ... [Published Georgetown University Hoya - Sep 15 2014]
First reported Sep 11 2014 - Updated Sep 12 2014 - 1 reports

Why Drug Prices Never Come Down in One Quote

Brace yourself for one amazing – and revealing – statement.Here is a Gilead executive attempting to justify the astronomical price of its hepatitis C treatment Sovaldi to Bloomberg : “ We didn’t base it on our R&D costs, and we didn’t base it on our acquisition ... [Published Ahip Hi-Wire - Sep 11 2014]
First reported Sep 08 2014 - Updated Sep 09 2014 - 4 reports

Sun Pharma settles litigation for generic Gleevec in US

Sun Pharmaceutical Industries today announced that one of its subsidiaries has executed a settlement agreement with Novartis Pharmaceuticals Corporation stipulating a dismissal of the lawsuits filed in the United States against the Company regarding submission ... [Published MyIris - Sep 09 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

UPDATE: What health insurance will really cost you next year

This holds particularly true for boomers and others with more complex medical needs. "Most of us as we age, statistically, see doctors more often and take more drugs," said Kev Coleman, head of research and data at HealthPocket, a health-insurance comparison ... [Published Morningstar.com - Sep 04 2014]
First reported Aug 30 2014 - Updated Aug 30 2014 - 3 reports

Novartis fails to report side effects, fatality

6:52 pm, August 30, 2014 Jiji PressNovartis Pharma K.K. said it has failed to report to the health ministry at least 2,579 cases of serious side effects, including a fatality, from its drugs for leukemia and other diseases even though its employees ... [Published PharmaGossip - Aug 30 2014]

Quotes

"As and when drugs go off-patent we expect this process will continue giving patients, doctors and payers wider choice of treatment options at a range of prices. However, it is important to remember the investment and research conducted by innovative bio-pharmaceutical companies making the long-term savings offered by generics possible. This investment brings us new therapies, new drugs, and supports the generics industry worldwide" he added
"This is part of an ongoing campaign by certain sections of the US industry to create pressure on the Obama Administration to force India to modify its IP regime to suit their commercial interests. They want India to go beyond TRIPS for protection and enforcement of their IPRs. However, India has sought to strike a balance between producers and users of innovation. Any change in this delicate balance will be at the cost of patients as medicines will become inaccessible and unaffordable for 99% of Indians" , D G Shah, secretary general Indian Pharmaceutical Alliance, which represents domestic companies said
"With target-medication over the past decade, the disease has become much more treatable" said Kwong Yok-lam, chair professor at the University of Hong Kong's department of medicine
"##STR00003## wherein: any one or two of X sub.1, X sub.2 and X sub.3 is a N atom and the remaining two or one of X sub.1, X sub.2 and X sub.3 are independently CR.sup.13; Y is selected from SO.sub.2 and SO; R sup.1, R sup.2, R sup.3, and R sup.7 and the one or two R sup.13 groups are each independently selected from H and R sup.10, R sup.10 is selected from R sup.8, alkyl, aryl, heteroaryl and combinations of two or more thereof and combinations with one or more R sup.9, or R sup.10 is one or more moieties R sup.11 linking one or more alkyl, alkoxy, aryl, heteroaryl or R sup.8 or R sup.9 groups or combinations thereof, directly or via a moiety selected from alkylene, arylene, heteroarylene or combinations thereof, wherein alkyl, aryl, heteroaryl groups or moieties thereof may be substituted with one or more groups R sup.12, or R sup.10 is selected from a group R sup.12; R sup.11 is selected from O--, N--, NH--, N dbd.C, CO--, COO--, CON--, CONH--, SO.sub.2--, SO.sub.2N--, SO.sub.2NH--; R sup.12 is selected from halogeno, NH.sub.2, NO.sub.2, CN, OH, COOH, CONH.sub.2, C(.dbd.NH)NH.sub.2, SO.sub.3H, SO.sub.2NH.sub.2, SO.sub.2CH.sub.3, OCH.sub.3, OCH.sub.2CH.sub.3, CF.sub.3; R sup.8 and R sup.9 comprise one or more solubilising moieties independently chosen from i) neutral hydrophilic groups, ii) ionisable organic acids, iii) ionisable organic bases, iv) chemical functions or moieties providing covalent or non-covalent attachment or binding to a solid phase or an immobile receptor and combinations thereof; R sup.4, R sup.5 and R sup.6 are each independently selected from H and R sup.10, or two of R sup.4 to R sup.6 are linked to form a cyclic ether or amine containing one or more additional oxygen or nitrogen atoms."

More Content

All (116) | News (87) | Reports (0) | Blogs (29) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
US drug lobby awaits Prime Minister Narendra Mo... [Published DNA India - 4 hours ago]
US takes a dig at India’s IPR regime [Published Times of India - 8 hours ago]
La Grange cancer survivor lobbies for more rese... [Published Doings LaGrange - 9 hours ago]
Cancer survivor numbers triple from 1970s [Published Columbian.com - 14 hours ago]
Leukemia sufferers make drug plea [Published Hong Kong Standard - Sep 21 2014]
New medications are making inroads in cancer ba... [Published Minneapolis Star Tribune - Sep 20 2014]
New Drug Saves Man with Non-Hodgkin's Lymphoma [Published WJBF-TV - Sep 20 2014]
We need an ecosystem of innovation to retain ou... [Published Hindu Business Line - Sep 19 2014]
Gilead Emerging Market Agreement: Huge Win For ... [Published Seeking Alpha - Sep 19 2014]
Synergy in drug research success [Published Business Times Singapore - Sep 19 2014]
Patent Issued for Compounds for Treating Prolif... [Published 4 Traders - Sep 18 2014]
ASCO 50th Anniversary Poll Names the Top 5 Adva... [Published American Society of Clinical Oncology - Sep 17 2014]
Epizyme announces management changes [Published Individual.com - Sep 17 2014]
Cancer Survivor Numbers Triple From 40 Years Ag... [Published Bloomberg - Sep 16 2014]
The Downfall of Pharmaceutical Innovation [Published Georgetown University Hoya - Sep 15 2014]
Epizyme Appoints Chief Development Officer [Published Contract Pharma - Sep 15 2014]
Sun Pharma: Is the Street's nervousness justified? [Published Business Standard India - Sep 12 2014]
Why Drug Prices Never Come Down in One Quote [Published Ahip Hi-Wire - Sep 11 2014]
7 Threats to Cancer Care [Published General Medicine eJournal - Sep 10 2014]
Sun Pharma settles litigation for generic Gleev... [Published MyIris - Sep 09 2014]
Sun Pharma climbs after settlement of lawsuit w... [Published MyIris - Sep 09 2014]
Novartis Drags DRL to US Court Over Patent Infr... [Published New Indian Express - Sep 09 2014]
'IPR policy on the cards to protect national in... [Published Economic Times - Sep 09 2014]
Novartis drags DRL to US court for patent viola... [Published Financial Express - Sep 08 2014]
Court Report - September 2014 [Published JD Supra - Sep 08 2014]
Sun Pharma shares gain; Credit Suisse raises ta... [Published Moneycontrol.com - Sep 08 2014]
Why Is Novartis Investing in This $49 Billion M... [Published Motley Fool Discussion Boards - Sep 07 2014]
Science: a vision of hope [Published ABC Online - Sep 06 2014]
Blockbusters Differentiate Novartis [Published Morningstar.com - Sep 05 2014]
Wife Enters Southeasten Hoops Coach to Redbook ... [Published Winter Haven News Chief - Sep 05 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Novartis fails to report side effects, fatality [Published PharmaGossip - Aug 30 2014]
6:52 pm, August 30, 2014 Jiji PressNovartis Pharma K.K. said it has failed to report to the health ministry at least 2,579 cases of serious side effects, including a fatality, from its drugs for leukemia and other diseases even though its employees ...
Improving the FDA, Ctd [Published The Daily Dish | By Andrew Sullivan - Aug 16 2014]
by Elizabeth Nolan Brown Should the U.S. Food and Drug Administration inch closer to Europe’s drug approval model , in which certified, independent bodies can (and compete to) review new products? A Dish reader says, hey, it worked for the Federal ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 05 2014]
Phenotypic Assays in Cancer Drug Discovery [Published In the Pipeline - Jul 24 2014]
The topic of phenotypic screening has come up around here many times, as indeed it comes up very often in drug discovery. Give your compounds to cells or to animals and look for the effect you want: what could be simpler? Well, a lot of things could, ...
The High Cost of Second-Generation TKIs for CML... [Published PR Newswire: General Business - Jul 15 2014]
BURLINGTON, Mass., July 15, 2014 /PRNewswire/ -- Decision Resources Group finds that, despite the fact that the treatment armamentarium for chronic myeloid leukemia (CML) in Brazil and Mexico includes all three tyrosine kinase inhibitors (TKIs)—Novartis' ...
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.